Regeneron announces positive topline results from phase 3 trial of evinacumab for HoFH
Regeneron announced positive pivotal Phase 3 results for evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody, in patients with homozygous familial hypercholesterolemia. Patients with HoFH have severely elevated levels of LDL cholesterol. August 14, 2019